IBRX ImmunityBio Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: IBRX

Price (delayed)

$9.15

Market cap

$6.17B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.15

Enterprise value

$6.78B

NantKwest (NASDAQ: NK) is an innovative, clinical-stage, immunotherapy company focused on harnessing the power of the innate immune system to treat cancer and infectious diseases. NantKwest is the leading producer ...

Highlights
The company's gross profit has surged by 159% YoY and by 12% QoQ
ImmunityBio's revenue has surged by 159% YoY and by 12% QoQ
ImmunityBio's equity has decreased by 43% QoQ and by 31% YoY
ImmunityBio's net income has decreased by 40% YoY and by 27% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: https://www.nantkwest.com/
Peers: OMER OMGA

Key stats

What are the main financial stats of IBRX
Market
Shares outstanding
673.95M
Market cap
$6.17B
Enterprise value
$6.78B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
7,482.34
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10,905.7
Earnings
Revenue
$622,000
EBIT
-$454.04M
EBITDA
-$429.41M
Free cash flow
-$397.34M
Per share
EPS
-$1.15
Free cash flow per share
-$0.78
Book value per share
-$0.88
Revenue per share
$0
TBVPS
$0.96
Balance sheet
Total assets
$504.45M
Total liabilities
$1.09B
Debt
$882.14M
Equity
-$586.99M
Working capital
$235.8M
Liquidity
Debt to equity
-1.5
Current ratio
5.05
Quick ratio
4.61
Net debt/EBITDA
-1.44
Margins
EBITDA margin
-69,037.6%
Gross margin
100%
Net margin
-93,761.4%
Operating margin
-58,239.5%
Efficiency
Return on assets
-148.4%
Return on equity
N/A
Return on invested capital
-65.3%
Return on capital employed
-101.8%
Return on sales
-72,996.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

IBRX stock price

How has the ImmunityBio stock price performed over time
Intraday
2.01%
1 week
24.49%
1 month
60.25%
1 year
173.13%
YTD
82.27%
QTD
70.39%

Financial performance

How have ImmunityBio's revenue and profit performed over time
Revenue
$622,000
Gross profit
$622,000
Operating income
-$362.25M
Net income
-$583.2M
Gross margin
100%
Net margin
-93,761.4%
The company's gross profit has surged by 159% YoY and by 12% QoQ
ImmunityBio's revenue has surged by 159% YoY and by 12% QoQ
ImmunityBio's operating margin has soared by 60% YoY and by 10% from the previous quarter
The net margin rose by 46% year-on-year but it has declined by 14% since the previous quarter

Growth

What is ImmunityBio's growth rate over time

Valuation

What is ImmunityBio stock price valuation
P/E
N/A
P/B
N/A
P/S
7,482.34
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10,905.7
ImmunityBio's EPS has decreased by 11% YoY and by 10% QoQ
ImmunityBio's equity has decreased by 43% QoQ and by 31% YoY
ImmunityBio's revenue has surged by 159% YoY and by 12% QoQ
The P/S is 72% more than the 5-year quarterly average of 4342.1

Efficiency

How efficient is ImmunityBio business performance
ImmunityBio's return on sales has surged by 50% YoY but it has decreased by 22% QoQ
IBRX's return on assets is down by 27% year-on-year and by 16% since the previous quarter
The company's return on invested capital fell by 13% YoY and by 8% QoQ

Dividends

What is IBRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IBRX.

Financial health

How did ImmunityBio financials performed over time
The total assets is 54% less than the total liabilities
ImmunityBio's quick ratio has soared by 116% from the previous quarter
The current ratio has soared by 112% from the previous quarter
ImmunityBio's equity has decreased by 43% QoQ and by 31% YoY
The debt rose by 23% since the previous quarter and by 22% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.